

NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

Company



2024/08/16 17:31:02

Price

7.60 CHF

Difference 5.26%(0.38)



Contact Details

NEWRON PHARMACEUTICALS
SPA

Tel: +39-02-610-3461

--

Fax: +39-02-610-34654

via Antonio Meucci 3

Web:

<https://www.newron.com/>

20091 Bresso

E-mail: info@newron.com

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	18,271,000		28,134,000		40,852,000	
Common stock capital		3,318,000		3,524,000		3,698,000
Fixed assets	5,777,000		8,592,000		11,458,000	
Equity capital of a company		-27,806,000		-13,853,000		3,219,000
Cash and cash equivalents	5,892,000		13,255,000		25,923,000	
Accrued liabilities		383,000		468,000		602,000
Other assets	-		-		-	
Current liabilities		26,893,000		4,977,000		3,786,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		24,961,000		45,602,000		45,306,000
Different income		-		-		-
Other liabilities		439,000		217,000		220,000
Total assets	24,048,000	24,048,000	36,727,000	36,727,000	52,311,000	52,311,000

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	-	-	-
Equity ratio	-115.63%	-37.72%	6.15%
Debt-equity ratio	-186.49%	-365.11%	1,524.91%

Others

	2023	2022	2021
Tax Expense Rate	-0.15%	-0.12%	-0.11%

NEWRON PHARMACEUTICALS SPA

ISIN: IT0004147952 WKN: 2791431 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	8,799,000	6,116,000	6,226,000
Net income	-15,762,000	-17,558,000	-16,102,000
EBIT	-11,906,560	-13,989,840	-13,697,239
Operating income before taxes	-15,739,000	-17,537,000	-16,084,000
Cash Flow	-9,851,000	-11,133,000	-12,367,000
Net interest income	-4,478,000	-4,307,000	-3,130,000
Research and development expenses	12,710,000	11,981,000	11,522,000
Income taxes	23,000	21,000	18,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	-	-	-

Board of Directors

Ulrich Köstlin	Chairman of Supervisory Board
Luca Benatti	Member of Supervisory Board
Patrick Langlois	Member of Supervisory Board
Gillian Dines	Member of Supervisory Board
Margarita Chavez	Member of Supervisory Board

Members of Management Board

Stefan Weber	Chairman of Managing Board
Dennis Dionne	Member of Executive Committee
Filippo Moriggia	Member of Executive Committee
Laura Faravelli	Member of Executive Committee
Ravi Anand	Member of Executive Committee
Roberto Galli	Member of Executive Committee